New Swiss research institute to pioneer immune engineering and global child health

FHS
June 19, 2024
6:48 am

“Swiss research institute established to focus on immune engineering and advancing global child and adolescent health.”

MHRA approves Napp’s Rezzayo for invasive candidiasis

Share this article Rezzayo is indicated to be given as a weekly intravenous drip for a minimum of 14 days until Candida is no longer

January 30, 2024

China’s NMPA accepts NDA for AnHeart lung cancer therapy

Share this article Taletrectinib is intended to treat adult patients with locally advanced or metastatic ROS1-positive NSCLC. Credit: Stokkete / Shutterstock.com. China’s National Medical Products

November 23, 2023

Conference call on the results for the 3rd quarter 2023/24 (ending 30 June 2024) on 14 August 2024 – Biotech Investments

EQS-News: Douglas AG / Key word(s): 9 Month figures/Conference Conference call on the results for the 3rd quarter 2023/24 (ending 30 June 2024) on 14

August 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.